Solvation effects are responsible for the reduced inhibitor affinity of some HIV-1 PR mutants

Protein Science

Volumn 6, Issue 5, 1997, Pages 1024-1030

  Sussman, Fredy ^a,b   Villaverde, M Carmen ^a,b   Davis, Alan ^a  

^a OKLAHOMA CITY UNIVERSITY   (United States)

^b OKLAHOMA MEDICAL RESEARCH FOUNDATION   (United States)

Author keywords

free energy scoring function; HIV 1 Protease; inhibitor affinity; resistance mutations; solvation effects

Indexed keywords

PROTEINASE; VIRUS ENZYME; VIRUS PROTEIN;

ARTICLE; BINDING AFFINITY; DRUG RESISTANCE; ENZYME ACTIVITY; ENZYME INHIBITION; HUMAN IMMUNODEFICIENCY VIRUS; MUTATION; PRIORITY JOURNAL; PROTEIN ANALYSIS; SOLVATION;

EID: 0030902235     PISSN: 09618368     EISSN: None     Source Type: Journal    
DOI: 10.1002/pro.5560060508     Document Type: Article

References (28)

1. Brooks BR, Bruccoleri RE, Olafson BD, States DJ, Swaminathan S, Karplus M. 1983. CHARMM: a program for macromolecular energy, minimization, and dynamics calculations. J Comput Chem 4:187-217.
2. Beveridge DL, Di Capua FM. 1989. Free energy via molecular simulation: Applications to chemical and biomolecular systems. Annu Rev Biophys Biophys Chem 18:431-492.
3. Chothia C. 1976. The nature of the accessible and buried surfaces in proteins. J Mol Biol 105:1-14.
4. Condra JH, Schleif WA, Blahy OM, Gabryelski LJ, Graham DJ, Quintero JC, Rhodes A, Robbins HL, Roth E, Shivaprakash M, Titus D, Yang T, Teppler H, Squires KE, Deutsch PJ, Emini EA. 1995. In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors. Nature 374:569-571.
5. Dejaegere A, Karplus M. 1996. Analysis of coupling schemes in free energy simulations: A unified description of nonbonded contributions to solvation free energies. J Phys Chem 100:11148-11164.
6. El-Farrash MA, Kuroda MJ, Kitazaki T, Masuda T, Kato K, Hatanaka M, Harada S. 1994. Generation and characterization of a human immunodeficiency virus type I (HIV-1) mutant resistant to an HIV-1 protease inhibitor. J Virol 68: 233-239.
7. Harte WE Jr, Beveridge DL. 1993. Prediction of the protonation state of the active site aspartyl residues in HIV-1 protease-inhibitor complexes via molecular dynamics simulation. J Am Chem Soc 115:3883-3886.
8. 2-symmetric protease inhibitor. J Virol 68:2016-2020.
9. Hong L, Trehame A, Hartsuck JA, Foundling S, Tang J. 1996. Crystal structures of complexes of a peptidic inhibitor with wild-type and two mutant HIV-1 proteases. Biochemistry 35:10627-10633.
10. Jackson RM, Stemberg MJE. 1995. A continuum model for protein-protein interactions: Applications to the docking problem. J Mol Biol 250:258-275.
11. Jaskolski M, Tomasselli AG, Sawyer TK, Staples DG, Heinrikson RL, Schneider J, Kent SBH, Wlodawer A. 1991. Structure at 2.5 Å resolution of chemically synthesized human immunodeficiency virus type 1 protease complexed with a hydroxyethylene-based inhibitor. Biochemistry 30:1600-1609.
12. Kaplan AH, Michael SF, Wehbie RS, Knigge MF, Paul DA, Everitt L, Kempf DJ, Norbeck DW, Erickson JW, Swanstrom R. 1994. Selection of multiple human immunodeficiency virus type 1 variants that encode viral proteases with decreased sensitivity to an inhibitor of the viral protease. Proc Natl Acad Sci USA 97:5597-5601.
13. Kohl NE, Emini EA, Schleif WA, Davis LJ, Heimbach JC, Dixon RAF, Scolnick EM, Sigal IS. 1988. Active human immunodeficiency virus protease is required for viral infectivity. Proc Natl Acad Sci USA 85:4686-4690.
14. Krystek S, Stouch T, Novotny J. 1993. Affinity and specificity of serine endopeptidase-protein inhibitor interactions. J Mol Biol 234:661-679.
15. Lee B, Richards FM. 1971. The interpretation of protein structures: Estimation of static accessibility. J Mol Biol 55:379-400.
16. Lin Y, Lin X, Hong L, Foundling S, Heinrikson RL, Thaisrivongs S, Leelamanit W, Raterman D, Shah M, Dunn BM, Tang J. 1995. Effect of point mutations on the kinetics and the inhibition of human immunodeficiency virus type 1 protease: Relationship to drug resistance. Biochemistry 34:1143-1152.
17. Markowitz M, Mo H, Kempf DJ, Norbeck DW, Bath NT, Erickson JW, Ho DD. 1995. Selection and analysis of human immunodeficiency virus type 1 variants with increased resistance to ABT-538, a novel protease inhibitor. J Virol 69:701-706.
18. Nauchitel V, Villaverde MC, Sussman F. 1995. Solvent accessibility as a predictive tool for the free energy of inhibitor binding to the HIV-1 protease. Protein Sci 4:1356-1364.
19. Otto MJ, Garber S, Winslow DL, Reid CD, Aldrich P, Jadhav PK, Patterson CE, Hodge CN, Cheng YSE. 1993. In vitro isolation and identification of human immunodeficiency virus (HIV) variants with reduced sensitivity to C-2 symmetrical inhibitors of HIV type 1 protease. Proc Natl Acad Sci USA 90:7543-7547.
20. Serrano L, Sancho J, Hirshberg M, Fersht AR. 1992. α-helix stability in proteins. J Mol Biol 227:554-559.
21. Sharp KA, Honig B. 1990. Electrostatic interactions in macromolecules: Theory and applications. Annu Rev Biophys Biophys Chem 19:301-332.
22. Sharp KA, Nicholls A, Fine RF, Honig B. 1991. Reconciling the magnitude of the microscopic and macroscopic hydrophobic effects. Science 252:106-109.
23. Shen J, Wendoloski, J. 1995. Binding of phosphorus-containing inhibitors to thermolysin studied by the Poisson-Boltzmann method. Protein Sci 4:373-381.
24. Weng Z, Vajda S, Delisi C. 1996. Prediction of protein complexes using empirical free energy functions. Protein Sci 5:614-626.
25. Winslow DL, Stack S, King R, Scamati H, Bincsik A, Otto MJ. 1995. Limited sequence diversity of the HIV type 1 protease gene from clinical isolates and in vitro susceptibility to HIV protease inhibitors. Aids Res Hum Retroviruses 11:107-113.
26. Wlodawer A, Miller M, Jaskólski M, Sathyanarayana BK, Baldwin E, Weber IT, Selk LM, Clawson L, Schneider J, Kent SBH. 1989. Conserved folding in retroviral proteases: Crystal structure of a synthetic HIV-1 protease. Science 245:616-621.
27. Wlodawer A, Erickson JW. 1993. Structure-based inhibitors of HIV-1 protease. Annu Rev Biochem 62:543-585.
28. Zacharias M, Luty BA, Davis ME, McCammon JA. 1994. Combined conformational search and finite-difference Poisson-Boltzman approach for flexible docking. J Mol Biol 238:455-465.